Given the limited benefit shown by ALK1-blocking agents in clinical trials, we asked whether the expression status of the components of the signaling complex centered around ACVRL1 delineates tumor types that would benefit from ALK1 inhibition. Here, ACVRL1 is linked to neoplasm.